CCPA (2-Chloro-N6-cyclopentyladenosine)
(Synonyms: 2-氯-N6-环戊基腺苷) 目录号 : GC11665CCPA (2-Chloro-N6-cyclopentyladenosine) 是一种高选择性A1 adenosine receptors（A1R；Ki=0.4nM）激动剂，常用于探究A1受体介导的生理功能与信号机制。
Cas No.:37739-05-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
CCPA (2-Chloro-N6-cyclopentyladenosine) is a highly selective agonist for the A1 adenosine receptor (A1R; Kᵢ=0.4nM) and is commonly used to investigate physiological functions and signaling mechanisms mediated by the A1 receptor[1]. By activating the A1 receptor and inhibiting adenylate cyclase activity, CCPA reduces intracellular cyclic adenosine monophosphate (cAMP) levels, thereby modulating cardiac, neural, and metabolic systems[2-3]. CCPA has also been applied in exploring potential therapeutic strategies for diseases such as pulmonary fibrosis[4].
In vitro, pretreatment of SKBR-3 cells with CCPA (30μM) for 30 minutes, followed by co-incubation with GTP (50μM) for 72 hours, significantly inhibited GTP-induced cell death and increased cell viability[5]. Pretreatment of neonatal rat cardiomyocytes with CCPA (0.01–1μM) for 30 minutes prior to stimulation with angiotensin II (Ang II; 0.1μM) for 48 hours markedly suppressed Ang II-induced cardiomyocyte hypertrophy[6].
In vivo, daily intraperitoneal administration of CCPA (0.1mg/kg) to CD-1 mice subjected to a multiple-low-dose streptozotocin (40mg/kg) regimen over five consecutive days significantly reduced hyperglycemia in a model of type 1 diabetes[7]. A single intraperitoneal injection of CCPA (0.5 or 1mg/kg) in Wistar rats significantly altered the threshold and duration of hippocampal afterdischarges, demonstrating anticonvulsant effects[8].
References:
[1] Lohse MJ, Klotz KN, Schwabe U, et al. 2-Chloro-N6-cyclopentyladenosine: a highly selective agonist at A1 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol. 1988 Jun;337(6):687-9.
[2] Concas A, Santoro G, Mascia MP, et al. Anticonvulsant doses of 2-chloro-N6-cyclopentyladenosine, an adenosine A1 receptor agonist, reduce GABAergic transmission in different areas of the mouse brain. J Pharmacol Exp Ther. 1993 Nov;267(2):844-51.
[3] Concas A, Cuccheddu T, Floris S, et al. 2-Chloro-N6-cyclopentyladenosine (CCPA), an adenosine A1 receptor agonist, suppresses ethanol withdrawal syndrome in rats. Alcohol Alcohol. 1994 May;29(3):261-4.
[4] Della Latta V, Cabiati M, Rocchiccioli S, et al. The role of the adenosinergic system in lung fibrosis. Pharmacol Res. 2013 Oct;76:182-9.
[5] Hotani A, Kitabatake K, Tsukimoto M. Extracellular Guanosine and Guanine Nucleotides Decrease Viability of Human Breast Cancer SKBR-3 Cells. Biol Pharm Bull. 2024 Jan 1;47(1):14-22.
[6] Zhang X, Xia J, Qian D, et al. An adenosine A1 agonist 2-chloro-N6 cyclopentyladenosine inhibits the angiotensin II-induced cardiomyocyte hypertrophy through the calcineurin pathway. Cardiology. 2014;129(3):153-62.
[7] Németh ZH, Bleich D, Csóka B, et al. Adenosine receptor activation ameliorates type 1 diabetes. FASEB J. 2007 Aug;21(10):2379-88.
[8] Fabera P, Parizkova M, Uttl L, et al. Adenosine A1 Receptor Agonist 2-chloro-N6-cyclopentyladenosine and Hippocampal Excitability During Brain Development in Rats. Front Pharmacol. 2019 Jun 14;10:656.
CCPA (2-Chloro-N6-cyclopentyladenosine) 是一种高选择性A1 adenosine receptors（A1R；Ki=0.4nM）激动剂，常用于探究A1受体介导的生理功能与信号机制[1]。CCPA能够激活A1受体并抑制腺苷酸环化酶活性，进而降低细胞内环磷酸腺苷（cAMP）水平，对心脏、神经和代谢等系统产生调节作用[2-3]。CCPA还被应用于探索肺纤维化等疾病的潜在治疗策略[4]。
在体外，CCPA（30μM）预处理SKBR-3细胞30分钟，随后加入GTP（50μM）共同培养72小时，CCPA可显著抑制由GTP诱导的细胞死亡，并提高细胞存活率[5]。CCPA（0.01-1μM）预处理新生大鼠心肌细胞30分钟，随后以血管紧张素II（AngII；0.1μM）刺激48小时，CCPA可显著抑制由AngII诱导的心肌细胞肥大[6]。
在体内，CCPA（0.1mg/kg）每日腹腔注射处理CD-1小鼠，在连续5天给予链脲佐菌素（40mg/kg）诱导的1型糖尿病模型中，显著降低了小鼠的高血糖水平[7]。CCPA（0.5或1mg/kg）单次腹腔注射处理Wistar大鼠，显著改变了海马癫痫后放电的阈值和持续时间，表现出抗惊厥的作用[8]。
| Cell experiment [1]: | |
Cell lines | SKBR-3 cells (human breast adenocarcinoma cell line) |
Preparation Method | SKBR-3 cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) at 37°C, 5% CO₂. Cells were treated with the A1 receptor agonist CCPA at a concentration of 30μM for 30 minutes prior to the addition of guanosine triphosphate (GTP). |
Reaction Conditions | 30μM; 30min pre-treatment. |
Applications | CCPA significantly suppressed GTP-induced cell death in SKBR-3 cells. Co-treatment with CCPA also caused a significant increase in the IC₅₀ of GTP, suggesting that the A1 receptor agonist antagonized the cytotoxic effect of GTP on breast cancer cells. |
| Animal experiment [2]: | |
Animal models | CD-1 mice (multiple-low-dose-streptozotocin-induced diabetes model) and NOD mice (cyclophosphamide-accelerated diabetes model) |
Preparation Method | CD-1 mice were treated with streptozotocin (40mg/kg; i.p.) for 5 consecutive days to induce diabetes. The selective A1 receptor agonist CCPA was administered daily at 0.1mg/kg via intraperitoneal injection throughout the 21-day experimental period. |
Dosage form | 0.1mg/kg; i.p.; 5 days |
Applications | CCPA significantly decreased MLDS-induced hyperglycemia in CD-1 mice, demonstrating moderate antidiabetic effects. However, CCPA efficacy was inferior to the nonselective adenosine receptor agonist NECA (0.03mg/kg). CCPA treatment also showed protective effects against pancreatic β-cell loss, though to a lesser extent compared to NECA. |
References: | |
| Cas No. | 37739-05-2 | SDF | |
| 别名 | 2-氯-N6-环戊基腺苷 | ||
| 化学名 | (2R,3R,4S,5R)-2-(2-chloro-6-(cyclopentylamino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol | ||
| Canonical SMILES | ClC(N=C12)=NC(NC3CCCC3)=C2N=CN1[C@@H]([C@@H]4O)O[C@H](CO)[C@H]4O | ||
| 分子式 | C15H20ClN5O4 | 分子量 | 369.81 |
| 溶解度 | <36.98mg/ml in ethanol; <36.98mg/ml in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7041 mL | 13.5205 mL | 27.0409 mL |
| 5 mM | 540.8 μL | 2.7041 mL | 5.4082 mL |
| 10 mM | 270.4 μL | 1.352 mL | 2.7041 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet